伏诺拉生与埃索美拉唑对胃食管反流病患者血清CGRP、5-HT及炎症因子水平的影响OA

Objective To investigate the effects of vonoprazan and esomeprazole on serum levels of CGRP,5-HT,and inflammatory factors in patients with gastroesophageal reflux disease(GERD).Methods 96 GERD patients admitted to Puyang People's Hospital from July 2022 to July 2024 were randomly divided into a control group and an observation group,with 48 cases in each.Both groups were treated with itopride;while the control group received combined treatment with esomeprazole,and the observation group received combined treatment with vonoprazan.Both groups continued to receive treatment for four weeks.The clinical efficacy,serum levels of CGRP,5-HT,and inflammatory factors between two groups were compared,and the occurrence of adverse reactions was recorded.Results Compared with the control group,the total effective rate of the observation group was significantly higher;and the post-treatment levels of CGRP,5-HT,IL-6,IL-1β,and TNF-α were significantly lower(P<0.05).However,there was no statistically significant difference in the incidence of adverse reactions between the two groups(P>0.05).Conclusion Compared with itopride combined with esomeprazole,itopride combined with vonoprazan has a better therapeutic effect in reducing serum levels of CGRP,5-HT,and inflammatory factors in GERD patients,and can more effectively alleviate the body's inflammatory response;moreover,the safety of the two combined regimens is comparable.